Research professionals are encouraged to use the contact information on the "Our Team" page of this site to get in touch with members of the NCPC team, or email us at ncpc@northwestern.edu for more information about chemoprevention trials.
Information regarding previous publications and findings can be found in the "Completed Trials" section of our website.
Do you have
Liver Cirrhosis?
Liver cancer rates are increasing in the United States, and elsewhere. Out of every 100 patients with liver cancer, only 18 will survive for 5 years or more. An important cause of liver cancer is liver cirrhosis, which results from hepatitis infections, fatty liver, or alcohol use. Currently, there are no known preventive medications that could reduce the risk of liver cancer in people with cirrhosis.
Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis
Principal Investigator: Marc T. Goodman, Ph.D, M.P.H.
Cedars-Sinai Medical Center
This study will test the effects of simvastatin in people with liver cirrhosis. Participants in this study will get either simvastatin or placebo, a pill that looks like the study drug but contains no medication. This will allow researchers to see if participants taking simvastatin show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have liver cirrhosis. We will enroll 80 participants.
You may be eligible if you:
-
Are someone with a diagnosis of liver cirrhosis
-
Have never taken a statin medication before
You may be reimbursed up to $450 for your time and participation in this study.
If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:
CEDARS-SINAI MEDICAL CENTER– Los Angeles, California
UNIVERSITY OF PUERTO RICO – San Juan, Puerto Rico
GEORGETOWN UNIVERSITY – Washington, D.C.
Additional Resources
Study Brochure
Cedars-Sinai Medical Center
Study Brochure
Northwestern University
Statins & Liver Health
Estatinas y salud hepática
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis
Principal Investigator: A. Ruth He, M.D.
Georgetown University
This study uses different doses of Polyphenon E® in people with liver cirrhosis. We want to see whether this green tea extract can decrease the level of a molecule called γ-OHPdG, that we think is an indicator of liver cancer risk. Participants will undergo a liver biopsy before and after treatment. 50 participants will be registered for this study.
You may be eligible if you:
-
Are someone with a diagnosis of liver cirrhosis
-
Are over the age of 18
You may be compensated up to $1200 for your participation, your time, and extra expenses (child care, travel, absence from work, etc).
If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:
GEORGETOWN UNIVERSITY MEDICAL CENTER – Washington, D.C.
UNIVERSITY OF PUERTO RICO COMPREHENSIVE CANCER CENTER – San Juan, Puerto Rico
Additional Resources
Informational Handout
QR Poster
Study Poster
About Polyphenon E®